Roivant Sciences: Primed For Growth With A De-Risked Pipeline
…
10,640$
-3,54%
Echtzeit-Aktienkurs Roivant Sciences Ltd.
Bid:
Ask:
Nachrichten zur Roivant Sciences Ltd. Aktie
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a…
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than…
Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript
…
Roivant Sciences: A Biotech Growth Play With Major Ambitions
…
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
…
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
…
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
…
Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript
…
Roivant Sciences Ltd. 2024 Q1 - Results - Earnings Call Presentation
…
Roivant Sciences: Executing On Huge Buyback Program With More To Come
…
Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript
…
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 8% and 10.86%, respectively, for the quarter ended March 2024.…
Moderna: Lizenzgebühren an Arbutus im Fokus - Aktienanalyse
New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Jefferies & Co:
Michael Yee, Analyst von Jefferies & Co, rät in einer aktuellen Aktienanalyse…
Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
…
Roivant Sciences stock target raised to $16 by Goldman Sachs By Investing.com
Roivant Sciences stock target raised to $16 by Goldman Sachs…